• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1,104
103
69
68
65

COUNTRY

63
19
16
10
9

CATEGORIES

  • 89
  • 128
  • 71
  • 72
  • 44
  • 43
  • 21
  • 16
  • 20
  • 22

PRICE

547
805
1,600
2,596

PUBLISHED

233
285
736
2,596

PRODUCT TYPE

2,449
72
61
12
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors - Product Thumbnail Image

Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors

This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual...

June 2013
FROM
Triple Analysis: Melanoma, Apoptosis and Peptides Triple Analysis: Melanoma, Apoptosis and Peptides - Product Thumbnail Image

Triple Analysis: Melanoma, Apoptosis and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

June 2013
FROM
Triple Analysis: Breast Cancer, Lung Cancer and Melanoma Triple Analysis: Breast Cancer, Lung Cancer and Melanoma - Product Thumbnail Image

Triple Analysis: Breast Cancer, Lung Cancer and Melanoma

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lung Cancer and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in...

June 2013
FROM
Triple Analysis: Breast Cancer, Melanoma and Pancreatic Cancer Triple Analysis: Breast Cancer, Melanoma and Pancreatic Cancer - Product Thumbnail Image

Triple Analysis: Breast Cancer, Melanoma and Pancreatic Cancer

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Melanoma and Pancreatic Cancer. Each of these three individual parts is evaluated according to standardized criteria...

June 2013
FROM
Triple Analysis: Melanoma, Prostate Cancer and Peptides Triple Analysis: Melanoma, Prostate Cancer and Peptides - Product Thumbnail Image

Triple Analysis: Melanoma, Prostate Cancer and Peptides

This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according...

June 2013
FROM
Triple Analysis: Melanoma, Apoptosis and Angiogenesis Triple Analysis: Melanoma, Apoptosis and Angiogenesis - Product Thumbnail Image

Triple Analysis: Melanoma, Apoptosis and Angiogenesis

This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis. Each of these three individual parts is evaluated...

June 2013
FROM
Triple Analysis: Melanoma, Protein Kinase Inhibitors and Peptides Triple Analysis: Melanoma, Protein Kinase Inhibitors and Peptides - Product Thumbnail Image

Triple Analysis: Melanoma, Protein Kinase Inhibitors and Peptides

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific...

June 2013
FROM
Triple Analysis: Melanoma, Antibodies and Peptides Triple Analysis: Melanoma, Antibodies and Peptides - Product Thumbnail Image

Triple Analysis: Melanoma, Antibodies and Peptides

This triple analysis focuses on cancer drug development strategies in Melanoma and by the two compound strategies of Antibodies and Peptides. Each of these three individual parts is evaluated according...

June 2013
FROM

Bioinformatics in IVD Testing

Computer diagnostics could offer opportunity for clinical laboratory professionals to add value to clinicians in diagnosing diseases. IT companies in collaboration with test vendors are developing computer...

June 2013
FROM

KOL Insight: Prostate Cancer: Competition Intensifies in Race to the Top

The Prostate Cancer market has seen a number of progressive changes in recent years The launches of Johnson & Johnson's Zytiga (abiraterone acetate) and Medivation/Astellas's Xtandi (enzalutamide) has...

June 2013
FROM
Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top - Product Thumbnail Image

Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top

Charting the Future Prostate Cancer Market Landscape The prostate cancer market has experienced substantial changes in the last five years with patent expiries of key compounds and approvals of new...

June 2013
FROM

Asia-Pacific Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017

The radiopharmaceuticals market in the Asia-Pacific region was valued at $500 8 million in 2012; it is poised to reach $824 9million in 2017 at a CAGR of 10 5% The market is broadly classified into...

May 2013
FROM

PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Chronic Myeloid Leukemia (CML) - Global Drug Forecast and Market Analysis to 2022 Summary Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized...

May 2013
FROM

Skin Cancer - Pipeline Review, H1 2013

Skin Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Skin Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

May 2013
FROM

Hepatic - Colorectal Metastasis - Pipeline Review, H1 2013

Hepatic - Colorectal Metastasis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Hepatic - Colorectal Metastasis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

May 2013
FROM

Mycosis Fungoides - Pipeline Review, H1 2013

Mycosis Fungoides – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Mycosis Fungoides - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

May 2013
FROM

Sezary Syndrome - Pipeline Review, H1 2013

Sezary Syndrome – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Sezary Syndrome - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

May 2013
FROM

Gastric Cancer - Pipeline Review, H1 2013

Gastric Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Gastric Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

May 2013
FROM

Malignant Glioma - Pipeline Review, H1 2013

Malignant Glioma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Malignant Glioma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

May 2013
FROM

Gynecological Cancer - Pipeline Review, H1 2013

Gynecological Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Gynecological Cancer - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

May 2013
FROM
Loading Indicator

Our Clients

Our clients' logos